Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis

April 10, 2024 updated by: Nanfang Hospital, Southern Medical University

Effect of Isomaltooligosaccharides on Intestinal Bacterial Translocation in Patients With Liver Cirrhosis: a Single-center, Single-arm Study

The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main question is to answer the changes of LPS after adminstration of IMO.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
18

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Jinjun Chen, PhD
  • Phone Number: 44-13902246336
  • Email: chjj@smu.edu.cn

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China
        • Recruiting
        • Nanfang Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age from 18-75.
  • Cirrhotic patients.
  • Decompensation event: ascites.
  • LPS>0.45EU/ml.

Exclusion Criteria:

  • Pregnant or breast-feeding.
  • Active bacterial or fungal infection.
  • Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage.
  • Diagnosis of EASL-ACLF.
  • Diarrhea.
  • Malignancy.
  • Anticipated short survival time.
  • Adverse reactions or allergies to oral carbohydrate preparations.
  • Substance abuse or addiction.
  • Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders).
  • Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions.
  • Be unsuitable for participating in this trial.
  • Participated in any drug trial within the past month
  • History of antibacterial or fungal use within 1 week prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Administration of IMO
Patients will be given IMO (20g/100ml) for 7 days.
Dietary supplement: Isomaltooligosaccharides (IMO)
Patients will still receive standard treatment, including medicine and other invasive treatment.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Changes of Lipopolysaccharide (LPS) in plasma
Time Frame: Before (Day-0) and after treatment (Day-8).
LPS will be tested by Tachypiens Amebocyte Lysate (TAL) test
Before (Day-0) and after treatment (Day-8).

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Changes of bacterial load in plasma
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Count the Colony-Forming Units (CFU) to value the bacterial load
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of infections (CRP) in plasma
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
C-reactive protein
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of infections (PCT) in plasma
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Procalcitonin，PCT
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of kidney failure (Cr) in plasma
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Creatinine，Cr
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of coagulation failure (INR) in plasma
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
International normalized ratio，INR
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of liver failure (TBIL) in plasma
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Total bilirubin，TBIL
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of Lipopolysaccharide (LPS) in plasma after 7-day non-treatment
Time Frame: After 7-day non-treatment (day 15).
LPS will be tested by Tachypiens Amebocyte Lysate (TAL) test
After 7-day non-treatment (day 15).
Incidence of bacterial infection
Time Frame: After treatment (Day-8) up to follow-up (Day-28)
All kinds of infection, including pneumonia, SBP, urine tract infection and so on.
After treatment (Day-8) up to follow-up (Day-28)
Development of acute-on-chronic liver failure
Time Frame: After treatment (Day-8) up to follow-up (Day-28)
Diagnosis of ACLF is based on the criteria of EASL-ACLF.
After treatment (Day-8) up to follow-up (Day-28)
Changes of Meld scores which evaluate severity of liver diseases.
Time Frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Model for End-Stage Liver Disease (MELD) is used to estimates a patient's chances of surviving their disease during the next three months. This numerical scale is used for adult patients waiting for a transplant. The MELD score ranges from 6 to 40 (gravely ill). The individual score tells you what is the urgency of undergoing a liver transplant during the next 90 days (three months).
Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
28-day mortality
Time Frame: Day-28
Day-28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Nanfang Hospital, Southern Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 25, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 2, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 12, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 18, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 12, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 10, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NFEC-2023-457

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings